Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $200 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a $200 price target.
July 13, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating on Alnylam Pharmaceuticals and maintained a $200 price target.
The news is directly about Alnylam Pharmaceuticals and its rating by Cantor Fitzgerald. The Neutral rating suggests that the analyst does not expect significant price movement in the short term. The maintained price target of $200 also indicates that the analyst's valuation of the company has not changed. Therefore, the short term impact on the stock price is likely to be neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100